Newswise — Among patients who underwent gall bladder removal for acute calculous cholecystitis, lack of postoperative antibiotic treatment did not result in a greater incidence of infections, according to a study in the July 9 issue of JAMA.
Acute calculous cholecystitis (inflamed and enlarged gall bladder along with abdominal pain) is the third most frequent cause of emergency admissions to surgical wards. In the United States, approximately 750,000 cholecystectomies (surgical removal of the gall bladder) are performed each year and about 20 percent of these operations are due to acute calculous cholecystitis. Many patients receive postoperative antibiotics with the intent to reduce subsequent infections, although there is limited information from controlled studies demonstrating benefit, according to background information in the article.
Jean Marc Regimbeau, M.D., Ph.D., of the Amiens University Medical Center, Amiens, France, and colleagues randomly assigned 414 patients with mild or moderate acute calculous cholecystitis to continue with a preoperative antibiotic regimen (amoxicillin plus clavulanic acid) or receive no antibiotics after cholecystectomy. The study was conducted at 17 medical centers between May 2010 and August 2012.
The researchers found that the postoperative infection rates were 17 percent in the nontreatment group and 15 percent in the antibiotic group. In a per protocol analysis involving 338 patients, the corresponding rates were both 13 percent. Based on a noninferiority (not worse than) margin of 11 percent established for this trial, the lack of postoperative antibiotic treatment was not associated with worse outcomes than antibiotic treatment. The two groups of patients had similar length of hospital stay and readmission rates.
The authors note that guidelines published by the Infectious Diseases Society of America and the World Society of Emergency Surgery recommend treatment with amoxicillin plus clavulanic acid or sulbactam after cholecystectomy for noncomplicated acute calculous cholecystitis. “In the present series, we did not observe a benefit of postoperative antibiotic treatment on infections for patients with [mild or moderate] acute calculous cholecystitis.”
“It is well known that continuation of antibiotic treatment increases costs and promotes the selection of multiresistant bacteria. In 2010, 37,499 cholecystectomies for acute calculous cholecystitis were performed in France, and 90 percent of these were for grades I and II [mild or moderate] acute calculous cholecystitis. Supposing that these patients did not really need postoperative antibiotics (which are generally prescribed for 5 days), we estimate that many days of antibiotic treatment could be avoided each year. Reduction of the use of unnecessary antibiotics is important given that there is an increasing antibiotic resistance and a higher incidence of antibiotic complications such as Clostridium difficile infection. Our study demonstrates that postoperative antibiotics following acute calculous cholecystitis are not necessary.”(doi:10.1001/jama.2014.7586; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Editorial: Clinical Trial Evidence to Advance the Science of Cholecystectomy
Joseph S. Solomkin, M.D., of the University of Cincinnati College of Medicine, Cincinnati, writes in an accompanying editorial that the two cholecystectomy-related trials in this issue provide important new evidence to better inform surgeons performing this procedure; “however, both studies have a frequently encountered limitation of surgical trials—lack of blinding. In many surgical trials, blinding is not possible, or in some cases, as with sham procedures, blinding may raise important ethical considerations.”
“Blinding in randomized trials avoids physician and patient perceptions of efficacy from influencing protocol adherence or outcome assessment. Blinding is usually associated with random treatment assignment, and the treating physician, the patient, and the outcome assessor do not know what intervention the patient received. Blinding and randomization minimize the risk of conscious and unconscious bias in clinical trials (performance bias) and interpretation of outcomes (ascertainment bias).”
Dr. Solomkin notes that randomized trials, even if blinding is not possible, contribute greatly to evidence-based recommendations for clinical practice guidelines. “The clinical trials by Regimbeau et al and Iranmanesh et al provide useful data that help answer important questions about the management of patients undergoing cholecystectomy.”(doi:10.1001/jama.2014.7588; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor’s Note: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
# # #